Dr. Reddy’s inks COVID-19 licensing deal amid furore over IP waiver
13-05-2021
Svetlana Lukienko / Shutterstock.com
Indian pharmaceutical company Dr Reddy’s has agreed a deal to buy global intellectual property rights to a generic version of GSK’s deep vein thrombosis (DVT) treatment Arixtra (fondaparinux sodium) as part of a $17.5 million deal with a partner company.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Dr. Reddy’s Laboratories, GSK, Alchemia, patent, fondaparinux sodium